Lipid catabolism via CPT1 as a therapeutic target for prostate cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2361-2371

  Schlaepfer, Isabel R ^a   Rider, Leah ^a   Rodrigues, Lindsey Ulkus ^a   Gijón, Miguel A ^a   Pac, Colton T ^a   Romero, Lina ^a   Cimic, Adela ^b   Sirintrapun, S Joseph ^b,c   Glodé, L Michael ^a   Eckel, Robert H ^a   Cramer, Scott D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; ETOMOXIR; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPOXIDE; LACTONE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; FATTY ACID OXIDATION; GAS CHROMATOGRAPHY; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIPID ANALYSIS; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; LIPOLYSIS; LNCAP CELL LINE; MALE; MASS SPECTROMETRY; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMIC THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOUSE; NUDE MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; EPOXY COMPOUNDS; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; LIPID METABOLISM; MALE; METABOLISM; MICE; MICE, NUDE; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926618078     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0183     Document Type: Article

References (48)

1. Carlsson S, Vickers AJ, Roobol M, EasthamJ, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012;30:2581-4.
2. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
3. Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat 2012;98:1-10.
4. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65.
5. Vavere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008;49:327-34.
6. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011;223:283-94.
7. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004;64:2070-5.
8. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
9. Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol 2007;14:704-9.
10. Carracedo A, Cantley LC, Pandol fi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013;13:227-32.
11. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.
12. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010;140:49-61.
13. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010;120:142-56.
14. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemelio M, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 2002;16:1550-7.
15. Pike LS, Smift AL, Croteau NJ, Ferrick DA,WuM. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 2011;1807:726-34.
16. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 2006;3:490-8.
17. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000;99:27-35.
18. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008;123:476-83.
19. BarclayWW,Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 2005;146:13-8.
20. Schlaepfer IR, Hitz CA, Gijon MA, Bergman BC, Eckel RH, Jacobsen BM. Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Mol Cell Endocrinol 2012;363:111-21.
21. Consitt LA, Bell JA, Koves TR, Muoio DM, Hulver MW, Haynie KR, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals. Diabetes 2010;59:1407-15.
22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and puri fication. Can J Biochem Physiol 1959;37:911-7.
23. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005;36:207-24.
24. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009;69:6027-32.
25. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002;132:3191-4.
26. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res 2011;90:202-9.
27. Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M, Kulik G. Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS ONE 2009;4:e6224.
28. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34.
29. Kraskiewicz H, FitzGerald U. InterfERing with endoplasmic reticulum stress. Trends Pharmacol Sci 2012;33:53-63.
30. Little JL, Wheeler FB, Koumenis C, Kridel SJ. Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 2008;7:3816-24.
31. Connor JH, Weiser DC, Li S, Hallenbeck JM, Shenolikar S. Growth arrest and DNA damage-inducible protein GADD34 assembles a novel signaling complex containing protein phosphatase 1 and inhibitor 1. Mol Cell Biol 2001;21:6841-50.
32. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy 2010;6: 239-47.
33. Taniguchi M, Kitatani K, Kondo T, Hashimoto-Nishimura M, Asano S, Hayashi A, et al. Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J Biol Chem 2012;287:39898-910.
34. Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res 2012;51:50-62.
35. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-8.
36. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101:519-32.
37. Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase. Science 2008;321:1315-22.
38. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996;137:4468-74.
39. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
40. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
41. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013;110:11988-93.
42. Van de Sande T, Roskams T, Lerut E, Joniau S, Van PH, Verhoeven G, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/ PKB. J Pathol 2005;206:214-9.
43. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008;27 Suppl 1:S53-70.
44. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic reticulum stress triggers autophagy. J Biol Chem 2006;281:30299-304.
45. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest 2012;122:4621-34.
46. Tsunekawa-Imai N, Miwa H, Shikami M, Suganuma K, Goto M, Mizuno S, et al. Growth of xenotransplanted leukemia cells is influenced by diet nutrients and is attenuated with 2-deoxyglucose. Leuk Res 2013;37:1132-6.
47. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, et al. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res 2008;68:3066-73.
48. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2: ERG. J Natl Cancer Inst 2013;105:1881-90.